Median announces clinical trials expansion

Imaging software developer Median Technologies said its order backlog increased 134% during 2014 to reach 11 million euros.

The company noted it has been awarded projects to interpret and manage medical images for five new studies, including two phase III studies for non-small lung cancer, a phase II study for breast cancer, a phase I/II study for colorectal cancer, and a phase I study for solid tumor cancers. The awards represent a total value of approximately 3.24 million euros, according to the vendor.

Page 1 of 551
Next Page